These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31235357)

  • 1. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
    Mitchell KG; Parra ER; Nelson DB; Zhang J; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    J Thorac Cardiovasc Surg; 2019 Sep; 158(3):911-919.e6. PubMed ID: 31235357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
    J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
    Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
    Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
    Wang YQ; Zhang Y; Jiang W; Chen YP; Xu SY; Liu N; Zhao Y; Li L; Lei Y; Hong XH; Liang YL; Li JY; Zhang LL; Yun JP; Sun Y; Li YQ; Ma J
    J Immunother Cancer; 2019 Nov; 7(1):298. PubMed ID: 31722750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of V-set immunoregulatory receptor in malignant mesothelioma.
    Chung YS; Kim M; Cha YJ; Kim KA; Shim HS
    Mod Pathol; 2020 Feb; 33(2):263-270. PubMed ID: 31363159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
    Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
    Front Immunol; 2020; 11():839. PubMed ID: 32536910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER; Behrens C; Rodriguez-Canales J; Lin H; Mino B; Blando J; Zhang J; Gibbons DL; Heymach JV; Sepesi B; Swisher SG; Weissferdt A; Kalhor N; Izzo J; Kadara H; Moran C; Lee JJ; Wistuba II
    Clin Cancer Res; 2016 Dec; 22(24):6278-6289. PubMed ID: 27252415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Mitchell KG; Amini B; Wang Y; Carter BW; Godoy MCB; Parra ER; Behrens C; Villalobos P; Reuben A; Lee JJ; Weissferdt A; Moran CA; Fujimoto J; Sepesi B; Walsh GL; Vaporciyan AA; Hofstetter WL; William WN; Gibbons DL; Wang J; Hwu P; Swisher SG; Piwnica-Worms D; Kadara H; Wistuba II; Heymach JV; Peng W; Cascone T
    Cancer Immunol Immunother; 2020 Aug; 69(8):1519-1534. PubMed ID: 32300858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
    Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
    Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Lea J; Panwar V; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2024 Aug; 37(8):100532. PubMed ID: 38848896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
    Parra ER; Jiang M; Machado-Rugolo J; Yaegashi LB; Prieto T; Farhat C; de Sá VK; Nagai MA; de Lima VCC; Takagaki T; Terra R; Fabro AT; Capelozzi VL
    Arch Pathol Lab Med; 2020 Oct; 144(10):1234-1244. PubMed ID: 32150457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.